Adaptimmune presents clinical results of NY-ESO TCR therapeutic candidate at ASCO 2015
Adaptimmune Therapeutics plc, a clinical stage biopharmaceutical company focused on the use of TCR engineered T-cell therapy to treat cancer, today announced a poster presentation of data on its lead clinical...